AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE)

Launched by ERASME UNIVERSITY HOSPITAL · Nov 2, 2015

Keywords

ClinConnect Summary

The CHANCE trial is studying how to identify young girls with cancer who might be at risk of infertility later in life, especially after undergoing treatments like chemotherapy. While many children may go through normal puberty after treatment, some may have a reduced ability to produce eggs, which could lead to difficulties with having children in the future. The goal of this study is to find those girls who seem to develop normally but may still have a lower ovarian reserve, so they can receive specialized follow-up care and, if needed, fertility preservation options.

To be eligible for this trial, girls aged 3 to 14 who have been diagnosed with certain types of cancer and are receiving treatment might participate. This includes those at high risk, like those undergoing bone marrow transplants, as well as those with lower risks who are treated with chemotherapy for conditions such as lymphoma or neuroblastoma. Participants will be monitored closely, and the study aims to provide valuable information about their fertility health, helping doctors make better decisions about their future reproductive options. It's important to note that certain girls with specific medical histories or conditions won't be eligible for this study to ensure their safety.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• * Patients from 3 to 14 year old included - Belong to one of these 3 groups (modified from Wallace et al, 2005):
• • High risk : Conditioning therapy for bone marrow transplantation or pelvic irradiation
• • Moderate/Low risk : Pathologies treated with chemotherapy regimen with moderate or low risk of inducing ovarian function insufficiency: AML, osteosarcoma, Ewing sarcoma, neuroblastoma, non-Hodgkin lymphoma, Hodgkin lymphoma, soft tissue sarcoma, ALL, Wilms tumour, retinoblastoma.
• • No risk (control group) : patients with chronic benign diseases or malignancies who don't receive any chemotherapy or other gonadotoxic treatment.
• Exclusion Criteria:
• • CNS (central nervous system) irradiation, cerebral tumour
• • Current or previous ovarian disease/surgery
• • Familial history of premature ovarian failure (no iatrogenic or surgical origins)
• • Previous known severe chronic disease potentially affecting normal growth or puberty (diseases inducing malnutrition, anorexia, genetic/congenital disorders as Turner, Kallman, BPES(Blepharophimosis, ptosis, and epicanthus inversus syndrome) syndromes, uncontrolled severe diabetes, Cushing Syndrome, auto-immune diseases, cystic fibrosis, severe renal dysfunction)
• • Genetic/congenital disorders inducing mental retardation